Show notes
Jorge Garcia discusses the pembrolizumab and atezolizumab bladder cancer dangling accelerated approvals and the ODAC process
Jorge Garcia discusses the pembrolizumab and atezolizumab bladder cancer dangling accelerated approvals and the ODAC process